APTIVUS (tipranavir)
ANTIVIRAL-HIV (ANTIRETROVIRAL) PROTEASE INHIBITORS · HIV INFECTION
Boehringer Ingelheim
Drug class
Antiviral-HIV Boosted Protease Inhibitors
Antiviral HIV boosted protease inhibitors are an antiretroviral regimen category rather than an isolated chemical subclass, consisting of an HIV-1 protease inhibitor co-administered with a pharmacokinetic enhancing agent such as low-dose ritonavir or cobicistat. Read more about Antiviral-HIV Boosted Protease Inhibitors
29 drugs in this class 18 manufacturers
Drugs in Antiviral-HIV Boosted Protease Inhibitors
APTIVUS (tipranavir/vitamin E TPGS)
ANTIVIRAL-HIV (ANTIRETROVIRAL) PROTEASE INHIBITORS · HIV INFECTION
Boehringer Ingelheim
NORVIR (ritonavir)
ANTIVIRAL-HIV BOOSTED PROTEASE INHIBITORS · HIV INFECTION
ABBOTT
NORVIR (ritonavir)
ANTIVIRAL-HIV BOOSTED PROTEASE INHIBITORS · HIV INFECTION
ABBOTT
NORVIR (ritonavir)
ANTIVIRAL-HIV BOOSTED PROTEASE INHIBITORS · HIV INFECTION
ABBOTT
PREZISTA (darunavir)
ANTIVIRAL-HIV (ANTIRETROVIRAL) PROTEASE INHIBITORS · HIV INFECTION
JANSSEN PRODUCT
PREZISTA (darunavir)
ANTIVIRAL-HIV (ANTIRETROVIRAL) PROTEASE INHIBITORS · HIV INFECTION
JANSSEN PRODUCT
REYATAZ (atazanavir sulfate)
ANTIVIRAL-HIV (ANTIRETROVIRAL) PROTEASE INHIBITORS · HIV INFECTION
BMS PRIMARYCARE
REYATAZ (atazanavir sulfate)
ANTIVIRAL-HIV (ANTIRETROVIRAL) PROTEASE INHIBITORS · HIV INFECTION
BMS PRIMARYCARE
Filter & compare in the drug finder →
Opens the drug finder with Antiviral-HIV Boosted Protease Inhibitors preselected. Add indication or manufacturer filters there.
Antiviral HIV boosted protease inhibitors are an antiretroviral regimen category rather than an isolated chemical subclass, consisting of an HIV-1 protease inhibitor co-administered with a pharmacokinetic enhancing agent such as low-dose ritonavir or cobicistat.
The pharmacokinetic booster selectively inhibits cytochrome P450 3A4 enzymes, significantly elevating and prolonging circulating levels of the primary protease inhibitor to prevent the cleavage of viral Gag and Gag-Pol polyproteins into mature, infectious virions.
Characterized by a high genetic barrier to resistance, these boosted combinations are primarily utilized alongside nucleoside reverse transcriptase inhibitors for the management and treatment of HIV-1 infection in treatment-naive individuals and patients with prior antiretroviral exposure or suspected resistance.
-
nih.gov
Antiviral HIV boosted protease inhibitors are an antiretroviral regimen category rather than an isolated chemical subclass, consisting of an HIV-1 protease inhibitor co-administered with a pharmacokinetic enhancing agent such as low-dose ritonavir or cobicistat
-
hiv.gov
Antiviral HIV boosted protease inhibitors are an antiretroviral regimen category rather than an isolated chemical subclass, consisting of an HIV-1 protease inhibitor co-administered with a pharmacokinetic enhancing agent such as low-dose ritonavir or cobicistat Characterized by a high genetic barrier to resistance, these boosted combinations are primarily utilized alongside nucleoside reverse transcriptase inhibitors for the management and treatment of HIV-1 infection in treatment-naive individu...
-
nih.gov
Antiviral HIV boosted protease inhibitors are an antiretroviral regimen category rather than an isolated chemical subclass, consisting of an HIV-1 protease inhibitor co-administered with a pharmacokinetic enhancing agent such as low-dose ritonavir or cobicistat Characterized by a high genetic barrier to resistance, these boosted combinations are primarily utilized alongside nucleoside reverse transcriptase inhibitors for the management and treatment of HIV-1 infection in treatment-naive individu...
-
fda.gov
The pharmacokinetic booster selectively inhibits cytochrome P450 3A4 enzymes, significantly elevating and prolonging circulating levels of the primary protease inhibitor to prevent the cleavage of viral Gag and Gag-Pol polyproteins into mature, infectious virions
-
nih.gov
The pharmacokinetic booster selectively inhibits cytochrome P450 3A4 enzymes, significantly elevating and prolonging circulating levels of the primary protease inhibitor to prevent the cleavage of viral Gag and Gag-Pol polyproteins into mature, infectious virions
-
nih.gov
Characterized by a high genetic barrier to resistance, these boosted combinations are primarily utilized alongside nucleoside reverse transcriptase inhibitors for the management and treatment of HIV-1 infection in treatment-naive individuals and patients with prior antiretroviral exposure or suspected resistance
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.